Nevisense Go, a portable, non-invasive instrument that uses electrical impedance spectroscopy to assess the skin barrier, will be studied in clinical practice in hospitals in Switzerland.
WHY IT IMPORTANT
With 20% of children developing atopic dermatitis, SciBase, The developer of the AI technology, says the ability to predict who is at high risk for this type of eczema could greatly expand treatments before it develops – possibly preventing the disease and its complications. exacerbations may persist into adulthood.
The Swedish company, which develops augmented intelligence-based solutions for skin disorders, has announced a two-year partnership with Johnson & Johnson. This study is a validation test of how SciBase’s portable, non-invasive tool can help predict atopic dermatitis in infants.
Simon Grant, CEO of SciBase, said in a video released with the announcement: “We believe we can prevent them from contracting this often lifelong disease.
According to the SciBase website, a dysfunctional skin barrier has been demonstrated in allergic and autoimmune conditions and diseases, and studies show an increase in allergic and autoimmune diseases. worldwide, according to the SciBase website.
Dr Caroline Roduit, principal investigator of the study, said: ‘I work every day with the management of various childhood allergies, and it’s a growing problem.
“Allergic diseases have a spontaneous progression with atopic dermatitis being the first manifestation, often in infancy, followed by other allergic diseases, such as food allergies and allergies,” she said. allergic asthma”. “The ability to recognize these children early will help develop strategies to prevent allergies,” she explains.
Skin barrier assessment is a newer application to SciBase’s EIS technology, which is approved in the United States and European Union for use in the detection of melanoma and non-melanoma skin cancers.
In 2020, SciBase announced Nevisense will be used to measure skin properties including barrier function in a study by the Mt. Sinai aimed to look at how birth affects the risk of developing allergies.
Grant says that once developed, the solution could be used by clinicians in postpartum care and for parents to monitor at home.
TREND TO BIGGER
The use of AI to predict patient conditions is an area of growing cooperation and development.
Research published last year on a data study involving more than 20 hospitals worldwide demonstrated the ability of an algorithm to predict the oxygen levels of COVID-19 patients with more than 88 specificity. %.
Combining AI with precision medicine could also lead to personalized diagnoses, an area where major investments in healthcare technology are being made.
Matt Hocks, COO, said in Sioux Falls, South Dakota-based Sanford Health leverages machine learning to analyze data and identify patients who could benefit from proactive treatment.
“Precision medicine will allow us to focus our efforts on prevention and screening, early diagnosis and care to help keep our patients healthy and thriving for generations to come,” he said. IT news about healthcare while discussing health IT investments.
ON PROFILE
“The promise of the trial is that it’s non-invasive and can be used widely – in this study, the test will be done with Nevisense Go at the infant’s home,” Grant said. “We see the partnership as an important step in shaping a future where medical technology is accessible, non-invasive and personalized.”
Andrea Fox is the senior editor of Healthcare IT News.
Email: [email protected]
Healthcare IT News is a HIMSS publication.
